CLINICAL_TRIALS
trial_result
· 2021-01-22
Clinical Trial Update: Safety and Efficacy of LCI699 in Cushing's Disease Patients [Phase 2]
Summary
Phase 2 trial updates the safety and efficacy of LCI699 for Cushing's disease, with completed status and results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Novartis Pharmaceuticals | Conditions: Cushings Disease, Cushing Disease | Phase 2 | Status: COMPLETED | Results posted: 2021-01-22